How Treprostinil Medicine Can Treat Interstitial Lung Disease

This patent describes methods to treat a serious lung condition called interstitial lung disease (ILD) by giving patients the medicine treprostinil to reduce lung function decline and improve breathing capacity.

What it covers

This patent provides methods for treating interstitial lung disease (ILD), a condition that causes scarring in the lungs. The core of the method involves administering treprostinil to a patient. The goal is to reduce the worsening of lung function over time and to increase the patient's forced vital capacity (FVC), which is the maximum amount of air they can exhale after a deep breath. For example, a patient with ILD could receive treprostinil to help slow down the progression of their disease and improve their ability to breathe deeply.

What it doesn't cover

• —Does not cover treatments for interstitial lung disease that use different medications than treprostinil.
• —Does not cover the use of treprostinil to treat lung conditions other than interstitial lung disease.
• —Does not cover methods of improving lung function that do not involve administering treprostinil to a patient.
• —Does not cover preventing interstitial lung disease before it develops, only treating existing conditions.

The clever bit

The novelty lies in identifying treprostinil, a known drug, as a treatment specifically for interstitial lung disease to reduce pulmonary function decline and increase forced vital capacity, rather than its existing uses for other lung-related conditions.

Why it matters

Interstitial lung disease (ILD) is a severe and progressive condition that significantly impairs a patient's breathing and quality of life. Current treatments often only slow its progression. This patent matters because it proposes a new therapeutic application for treprostinil, a drug already known for treating other pulmonary conditions, offering a potential new avenue for managing ILD and improving patient outcomes.

Real-world examples

• 1.Existing treprostinil formulations (e.g., Remodulin, Tyvaso) adapted for ILD treatment.
• 2.Clinical trials exploring treprostinil's efficacy in patients with interstitial lung disease.